These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 18687705

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pulse pressure to vascular cells: novel methods for solving pathogenesis in cell migration.
    Ishida Y.
    Cardiovasc Res; 2008 Dec 01; 80(3):326-7. PubMed ID: 18829700
    [No Abstract] [Full Text] [Related]

  • 3. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
    Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, Tomochika H, Mogi M, Horiuchi M.
    J Pharmacol Exp Ther; 2006 Dec 01; 319(3):1081-7. PubMed ID: 16990512
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
    Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, Rakugi H, Ogihara T, Horiuchi M.
    Hypertension; 2004 Feb 01; 43(2):263-9. PubMed ID: 14707152
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.
    Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H, Okayama H, Mogi M, Higaki J, Horiuchi M.
    Am J Hypertens; 2009 Feb 01; 22(2):145-50. PubMed ID: 19057515
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of pulse pressure on vascular smooth muscle cell migration: the role of urokinase and matrix metalloproteinase.
    Redmond EM, Cahill PA, Hirsch M, Wang YN, Sitzmann JV, Okada SS.
    Thromb Haemost; 1999 Feb 01; 81(2):293-300. PubMed ID: 10064009
    [Abstract] [Full Text] [Related]

  • 17. Olmesartan inhibits angiotensin II-Induced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways.
    Kyotani Y, Zhao J, Tomita S, Nakayama H, Isosaki M, Uno M, Yoshizumi M.
    J Pharmacol Sci; 2010 Feb 01; 113(2):161-8. PubMed ID: 20508392
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Simultaneous treatment with azelnidipine and olmesartan inhibits apoptosis of Hl-1 cardiac myocytes expressing E334k cMyBPC.
    Bahrudin U, Ikeda N, Utami SB, Maharani N, Morikawa K, Li P, Sobirin MA, Hasegawa A, Sakata S, Endo R, Rifqi S, Shirayoshi Y, Yamamoto K, Ninomiya H, Hisatome I.
    Drug Res (Stuttg); 2013 Oct 01; 63(10):515-20. PubMed ID: 23740383
    [Abstract] [Full Text] [Related]

  • 20. Ethanol inhibits pulse pressure-induced vascular smooth muscle cell migration by differentially modulating plasminogen activator inhibitor type 1, matrix metalloproteinase-2 and -9.
    Cullen JP, Sayeed S, Kim Y, Theodorakis NG, Sitzmann JV, Cahill PA, Redmond EM.
    Thromb Haemost; 2005 Sep 01; 94(3):639-45. PubMed ID: 16268483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.